PubMed Duzel, A., Vlainic, J., Antunovic, M., Malekinusic, D., Vrdoljak, B., Samara, M., Gojkovic, S., Krezic, I., Vidovic, T., Bilic, Z., Sjekavica, I., Djuzel, A.R., Knezevic, M., Sever, A.Z., Lojo, N., Kokot, A., Sever, M., Drmic, D., Seiwerth, S., Sikiric, P
In practice, some patients respond to tirzepatide with more pronounced weight loss than semaglutide, but individual response varies
Alternatively, differences in storage and handling practices after purchase could account for the variation
10.1186/s12958-020-00613-z 134 ZhouL
Medicare beneficiaries who have sleep apnea, diabetes or fatty liver disease cant access the program, but their Medicare Part D insurance might cover their GLP-1s separately based on those diagnoses